ArticleBritish journal of haematology2026
Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Acute myeloid leukaemia (AML) patients with concurrent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), nucleophosmin 1 (NPM1) and DNA methyltransferase 3 alpha (DNMT3A) mutations exhibit heterogeneous treatment outcomes. To identify optimal strategies for this subset, we retrospectively analysed 2541 AML patients with next-generation sequencing from 2016 to 2023. Among them, 113 harboured triple mutations and had treatment outcomes: 79 received allogeneic haematopoietic stem cell transplantation (allo-HSCT), and 34 underwent continuous chemotherapy (CMT). Compared with CMT, allo-HSCT was associated with superior 2-year overall survival (OS) (62.2% vs. 17.8%, p < 0.001). However, no clear additional benefit from allo-HSCT was observed in patients who achieved composite complete remission (CRc) with DNMT3A measurable residual disease (MRD) negativity or complete remission with negative multiparameter flow cytometry MRD after the first cycle of CMT (CMT
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.